

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Atherosclerosis: Lessons Learned and Concepts Challenged (B2)

February 4-8, 2018 • Sagebrush Inn & Suites • Taos, New Mexico, USA

Scientific Organizers: Laura F. Michael, Gerard Pasterkamp and Sekar Kathiresan

Sponsored by MedImmune and Novo Nordisk A/S

Abstract & Scholarship Deadline: October 5, 2017 / Abstract Deadline: November 7, 2017 / Discounted Registration Deadline: December 7, 2017

SUNDAY, FEBRUARY 4

Arrival and Registration

MONDAY, FEBRUARY 5

The Natural History of Atherosclerotic Disease

Peter Libby, Brigham and Women's Hospital, USA
Requiem of the Vulnerable Plaque, Challenging Current Concepts

Sekar Kathiresan, Massachusetts General Hospital, USA
Inherited Basis for Myocardial Infarction

Gerard Pasterkamp, University Medical Center Utrecht, Netherlands
Geno-Phenotyping of the Vulnerable Plaque and Patient

Short Talk(s) Chosen from Abstracts

Workshop 1

Short Talks Chosen from Abstracts

Lipoprotein Risk Factors

Kiran Musunuru, University of Pennsylvania, USA
Therapeutic Genome Editing as a Cure for Atherosclerosis

Anne Tybjærg-Hansen, Rigshospitalet, Copenhagen University Hospital, Denmark
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights from Epidemiology, Genetics and Biology

Daniel J. Rader, University of Pennsylvania, USA
Functionalizing HDL Cholesterol

Marlys L. Koschinsky, Western University, Canada
Lipoprotein(a): Ready For Prime Time?

Poster Session 1

TUESDAY, FEBRUARY 6

Diabetes, Obesity and Atherosclerosis

Ruth McPherson, University of Ottawa Heart Institute, Canada
Is Obesity a Causal Risk Factor for Atherosclerosis?

Sudha B. Biddinger, Boston Children's Hospital, Harvard Medical School, USA
Beyond Hyperglycemia: Novel Mediators of Diabetes Associated Cardiovascular Disease

Joerg Heeren, University Medical Center Hamburg-Eppendorf, Germany
Protective Role of Brown Adipose in Atherosclerosis Development

Laura F. Michael, Eli Lilly and Company, USA
Diabetes and Atherosclerosis: Anti-Diabetic Agents that Improve CV Outcomes

Short Talk(s) Chosen from Abstracts

The Inflammation Hypothesis

Ziad Mallat, University of Cambridge, UK
Immune Modulation in Atherosclerosis

Jan Nilsson, Lund University, Sweden
Atheroprotective Immunity and Cardiovascular Disease: Therapeutic Opportunities and Challenges

Paul Ridker, Brigham and Women's Hospital, Harvard Medical School, USA
Anti-inflammatory Therapies for Chronic Atherosclerosis

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, FEBRUARY 7

The Milieu Exterieur

J. Mark Brown, Cleveland Clinic, USA
Diet, Gut Microbiota and Cholesterol Balance Influences Atherosclerosis

Seppo Yla-Herttuala, University of Eastern Finland, Finland
Epigenetics of Atherosclerosis

Robert E. Gerszten, Beth Israel Deaconess Medical Center, USA
Translating Exercise into Reduced Atherosclerosis Burden

Peter Clifton†, University of South Australia, Australia
Talk Title to be Announced

Short Talk(s) Chosen from Abstracts

Workshop 2

Short Talks Chosen from Abstracts

Crosstalk Among Organs

Viktoria Gusarova, Regeneron Pharmaceuticals, USA
Novel Therapeutic Approaches for Treatment of Atherosclerosis

Lilach O. Lerman, Mayo Clinic, USA
New Concepts in Atherosclerotic Renovascular Disease: Current Status

Joachim Herz, University of Texas Southwestern Medical Center, USA

Multitasking Therapeutics: Mutual Mechanisms behind Alzheimer's Disease and Atherosclerosis

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, FEBRUARY 8

Keynote Address

George D. Yancopoulos, Regeneron Pharmaceuticals, Inc., USA
The Impact of PCSK9 on Treating Atherosclerosis

Models and Biomarkers for Atherosclerotic Disease

Jacob Fog Bentzon, Centro Nacional de Investigaciones Cardiovasculares, Spain
Large Animal Models of Atherosclerosis - New Tools for Persistent Problems in Cardiovascular Research

James K. Min, Weill Cornell Medicine, USA
Predicting the Future: Coronary CT Angiography

Katey Rayner, University of Ottawa Heart Institute / University of Ottawa, Canada

New Inflammatory Drivers and Biomarkers of Atherosclerosis

Short Talk(s) Chosen from Abstracts

Workshop 3

Short Talks Chosen from Abstracts

Emerging Fields of Research

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Atherosclerosis: Lessons Learned and Concepts Challenged (B2)

February 4-8, 2018 • Sagebrush Inn & Suites • Taos, New Mexico, USA

Scientific Organizers: Laura F. Michael, Gerard Pasterkamp and Sekar Kathiresan

Sponsored by MedImmune and Novo Nordisk A/S

Abstract & Scholarship Deadline: October 5, 2017 / Abstract Deadline: November 7, 2017 / Discounted Registration Deadline: December 7, 2017

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Atherosclerosis: Lessons Learned and Concepts Challenged (B2)

February 4-8, 2018 • Sagebrush Inn & Suites • Taos, New Mexico, USA

Scientific Organizers: Laura F. Michael, Gerard Pasterkamp and Sekar Kathiresan

Sponsored by MedImmune and Novo Nordisk A/S

Abstract & Scholarship Deadline: October 5, 2017 / Abstract Deadline: November 7, 2017 / Discounted Registration Deadline: December 7, 2017

John J.P. Kastelein, University of Amsterdam, Netherlands

Emerging Therapies

Hester den Ruijter, UMC Utrecht, Netherlands

Cardiovascular Disease in Women

Salim Yusuf, McMaster University, Canada

How can we Reduce Premature CVD Globally in a Generation?

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

FRIDAY, FEBRUARY 9

Departure